generation run 2026-05-07
63 min completedmodel pipeline-v5plan not recordedrun/2dfe03d1…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- sparse_evidence
Reproduce
- inputs
- 33 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
16 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | delta-8-THC human clinical studies psychoactive effects | 6 | 3 | First controlled human comparison trials for delta-8-THC via different ROAs |
| 2 | PubMed | delta-8-THC synthesis production hemp CBD conversion isomerization | 1 | 1 | Documents CBD-to-delta-8-THC chemistry |
| 3 | PubChem | delta-8-tetrahydrocannabinol | 1 | 1 | Primary chemical identity data for substance brief |
| 4 | Web | delta-8-THC legal status DEA FDA scheduling 2026 | 10 | 3 | Legal status not available in academic databases |
| 5 | PubMed | delta-8-THC dependence tolerance withdrawal cannabinoid use disorder | 1 | 1 | Only published preclinical dependence study specific to delta-8-THC |
| 6 | ClinicalTrials.gov | delta-8-tetrahydrocannabinol | 6 | 4 | All directly relevant delta-8-THC clinical trials |
| 7 | OpenAlex | delta-8-THC tetrahydrocannabinol pharmacology | 15 | 1 | — |
| 8 | PubMed | delta-8 tetrahydrocannabinol product impurities NMR analysis distillate vaporizer | 1 | 1 | Only analytical study of commercial product impurity levels |
| 9 | PubMed | delta-8-tetrahydrocannabinol pharmacology receptor binding | 15 | 2 | Tagen review is primary comprehensive pharmacology reference; Wiley 2024 for cannabimimetic effects comparison |
| 10 | PubMed | delta-8-tetrahydrocannabinol public health hemp derived products regulation | 10 | 4 | Epidemiological data and public health implications |
| 11 | Web | delta-8-THC CB1 receptor Ki binding affinity comparison delta-9-THC nM values | 10 | 1 | Specific binding affinity values not available in abstract text of primary review |
| 12 | Web | delta-8 THC poison control adverse events CDC report 2021 2022 | 10 | 1 | Primary CDC public health alert for adverse events data |
| 13 | PubMed | delta-8-THC poison control center exposures United States | 5 | 3 | Toxicity and adverse event epidemiological data |
| 14 | PubMed | delta-8-tetrahydrocannabinol pharmacokinetics metabolism | 10 | 4 | PK data for metabolism section; rat data only at this point |
| 15 | PubMed | delta-8-THC nausea antiemetic children cancer | 1 | 1 | Key clinical data for antiemetic efficacy and historical use |
| 16 | PubMed | chemistry pharmacology delta-8-tetrahydrocannabinol review 2024 | 1 | 1 | Most comprehensive chemistry review including historical isolation date |
81 claims by section — every cited sentence, checked against its source
safety20 · 8 ok
Pediatric populations (absolute): Documented severe adverse events including loss of consciousness in children.supported
ER presentations including pediatric unconsciousness. can.2021.0097
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Children under 6 years are particularly vulnerable to serious adverse events following ingestion of Δ8-THC edible productssupported
Relationship between body weight-based doses of ingested Δ8-THC and clinical outcomes among children <6 years old. s40621-025-00617-6
Multiple pediatric patients have presented to emergency departments unconscious and unresponsivesupported
High-dose exposure causes medical emergencies, poison control calls, ER presentations including pediatric unconsciousness. can.2021.0097
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — not_supportednot supportedworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Cross-tolerance to the synthetic cannabinoid WIN 55,212-2 was observed, confirming a shared CB1-mediated mechanism.supported
cross-tolerance to WIN 55,212-2 j.drugalcdep.2022.109640
Claim in safety — inconclusiveinconclusiveworking →
Δ8-THC produces Δ9-THC-like discriminative stimulus effects in both male and female mice, a validated preclinical measure of abuse potentialsupported
Δ9-THC-like discriminative stimulus effects in mice. j.drugalcdep.2022.109640
Δ8-THC is expected to be metabolized via CYP3A4, CYP2C9, and CYP2C19supported
Major cannabinoids metabolized by CYP3A4, CYP2C9, CYP2C19. Δ8-THC mentioned as unregulated OTC product. fphar.2024.1282831
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Anticoagulant therapy (relative): Potential CYP2C9 interaction with warfarin.supported
Major cannabinoids metabolized by CYP3A4, CYP2C9, CYP2C19. Predicts drug-drug interactions with narrow therapeutic index drugs. fphar.2024.1282831
Pediatric populations (absolute): Documented severe adverse events including loss of consciousness in children.supported
Relationship between body weight-based doses of ingested Δ8-THC and clinical outcomes among children <6 years old. Pediatric toxicity investigation. s40621-025-00617-6
pharmacology17 · 12 ok
Δ-8-Tetrahydrocannabinol is a partial agonist at the cannabinoid CB1 receptor, the principal mediator of its psychoactive effectssupported
Δ8-THC is a partial agonist of CB1 receptor. bph.15865
CB1 activation proceeds through classical Gi/o protein coupling: inhibition of adenylyl cyclase (reducing intracellular cAMP), modulation of voltage-gated ion channels (inhibition of N-type and P/Q-type Ca²⁺ channels, activation of inwardly rectifying K⁺ channels), and downstream activation of the arachidonic acid cascade leading to prostaglandin E₂ (PGE₂) productionpartially supported
PGE2 mediates suppressive behavioral effects via CB1 receptor and arachidonic acid cascade. pmid:11166698
The role of the PGE₂ pathway in behavioral effects is supported by the finding that cyclooxygenase inhibitors (indomethacin, aspirin, diclofenac) antagonize Δ8-THC-induced behavioral suppression in rats.supported
Suppression antagonized by COX inhibitors. PGE2 mediates suppressive behavioral effects via CB1 receptor and arachidonic acid cascade. pmid:11166698
Claim in pharmacology — not_supportednot supportedworking →
At presynaptic CB1 receptors — densely expressed in the basal ganglia, cerebellum, and hippocampus — CB1 activation inhibits release of acetylcholine, GABA, and glutamate via retrograde signaling.partially supported
Very dense binding in basal ganglia, cerebellar molecular layer, hippocampus. jneurosci.11-02-00563.1991
Claim in pharmacology — inconclusiveinconclusiveworking →
The cannabimimetic nature of Δ8-THC's effects is confirmed by complete blockade with the selective CB1 inverse agonist rimonabant (SR141716A) in preclinical models.partially supported
physical dependence signs after rimonabant-precipitated withdrawal j.drugalcdep.2022.109640
Claim in pharmacology — inconclusiveinconclusiveworking →
The controlled human trials at Johns Hopkins (NCT05287256) include PK measurements, but full data await publicationsupported
The behavioral effects and pharmacokinetics of oral Δ8-THC remain poorly characterized. Within-subject crossover trial in healthy adults. j.drugalcdep.2025.112676
Intravenous administration in male rats yields a terminal elimination half-life of 13.9 ± 2.0 hours, a volume of distribution of 108.4 ± 8.9 L/kg (indicating extensive tissue sequestration consistent with high lipophilicity), and a systemic clearance of 5.6 ± 0.4 L/h/kg — a value exceeding hepatic blood flow and indicating significant extrahepatic clearance.supported
IV: clearance 5.6 L/h/kg, Vd 108.4 L/kg, t1/2 13.9h. Extrahepatic clearance indicated. bkaf105
Oral bioavailability from MCT oil vehicle is approximately 3.0% in rats, reflecting extensive first-pass hepatic metabolism and poor aqueous solubilitysupported
Oral: Cmax 13.4 ng/mL, Tmax 0.5h, bioavailability 3.0%. bkaf105
Nanoemulsion formulations improve oral bioavailability to 11–16.5%, with markedly faster absorption (Tmax ≈ 0.67–1 hour versus ≈ 6 hours for oil)partially supported
Nanoemulsions had shorter Tmax (0.667-1h) vs MCT oil (6h), ~4-fold higher early exposure. Bioavailability 11-16.5% nanoemulsion vs >21.5% MCT. s12249-023-02699-1
Plasma accumulation occurs with repeated daily dosing over 14 days.supported
Accumulation of D8-THC in plasma after 14 days observed. can.2023.0066
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
By structural analogy with Δ9-THC (differing only by double bond position), Δ8-THC is expected to be metabolized primarily via CYP3A4 and CYP2C9/2C19supported
Major cannabinoids metabolized by CYP3A4, CYP2C9, CYP2C19. Δ8-THC mentioned as unregulated OTC product. fphar.2024.1282831
This CYP profile creates potential for pharmacokinetic drug-drug interactions with co-administered medications metabolized by these enzymes, particularly those with narrow therapeutic indices.supported
Predicts drug-drug interactions with narrow therapeutic index drugs. fphar.2024.1282831
summary12 · 8 ok
Δ8-THC was first synthesized by Roger Adams and colleagues around 1941 and first isolated from cannabis in 1966supported
Notes 1966 isolation from Maryland marijuana at low yield. molecules29061249
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
The compound remained a pharmacological curiosity until Mechoulam and Abrahamov demonstrated complete prevention of chemotherapy-induced vomiting across 480 pediatric treatment sessions in 1995supported
480 total treatments. Vomiting completely prevented. pmid:7776837
Farm Bill, chemical isomerization of hemp-derived CBD into Δ8-THC created a rapidly expanding consumer market, prompting CDC and FDA safety advisories and eventual federal legislative closure of the regulatory gap.partially supported
Misinterpretation of 2018 Farm Bill... Several states called for regulation. can.2021.0097
Δ8-THC activates CB1 via classical Gi/o protein coupling — inhibiting adenylyl cyclase, modulating voltage-gated ion channels, and driving arachidonic acid cascade signaling to prostaglandin E₂ productionpartially supported
PGE2 mediates suppressive behavioral effects via CB1 receptor and arachidonic acid cascade. pmid:11166698
CB1 partial agonism is confirmed by full blockade with rimonabant (SR141716A) and by cannabimimetic tetrad activity requiring higher doses than Δ9-THC.partially supported
physical dependence signs after rimonabant-precipitated withdrawal, and Δ9-THC-like discriminative stimulus effects in mice. j.drugalcdep.2022.109640
Claim in summary — inconclusiveinconclusiveworking →
Tolerance develops through CB1 receptor downregulation, and physical dependence has been demonstrated in rodent models with rimonabant-precipitated withdrawalsupported
tolerance (via CB1 downregulation), cross-tolerance to WIN 55,212-2, physical dependence signs after rimonabant-precipitated withdrawal j.drugalcdep.2022.109640
Commercial product contamination — including uncharacterized synthesis byproducts and mislabeled potency — represents the dominant real-world safety concernsupported
Products contain impurities far beyond declared CoA levels. CBD-derived synthesis; valid concerns about impurities with unknown effects. molecules27206924
Claim in summary — inconclusiveinconclusiveworking →
No validated human pharmacokinetic parameters have been published; controlled human trial data from Johns Hopkins (NCT05287256) await full publication.supported
The behavioral effects and pharmacokinetics of oral Δ8-THC remain poorly characterized. j.drugalcdep.2025.112676
neuroscience6 · 3 ok
Tolerance and dependence are understood as the system's compensatory downregulation of CB1 density and coupling efficiency in response to sustained exogenous agonism.supported
tolerance (via CB1 downregulation), cross-tolerance to WIN 55,212-2, physical dependence signs after rimonabant-precipitated withdrawal j.drugalcdep.2022.109640
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — not_supportednot supportedworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
CB1 agonism modulates the mesolimbic dopamine pathway (ventral tegmental area → nucleus accumbens), the neural substrate for the reinforcing and euphoric properties of cannabinoids. Δ8-THC produces Δ9-THC-like discriminative stimulus effects in both sexes in mice, indicating engagement of overlapping reward circuitry.supported
Δ9-THC-like discriminative stimulus effects in mice. j.drugalcdep.2022.109640
A distinctive mechanistic finding for Δ8-THC is the role of prostaglandin E₂ (PGE₂) as a downstream mediator of behavioral effects. Δ8-THC-induced behavioral suppression in rats is antagonized by COX inhibitors — indomethacin, aspirin, and diclofenac — suggesting that the arachidonic acid cascade activated via CB1-Gi/o coupling produces PGE₂ that contributes to sedation and locomotor suppressionsupported
Suppression antagonized by COX inhibitors. PGE2 mediates suppressive behavioral effects via CB1 receptor and arachidonic acid cascade. pmid:11166698
clinical-evidence5 · 4 ok
Full quantitative results — effect sizes, dose-response data, and detailed pharmacokinetic parameters — await complete publication.supported
Controlled comparison of vaporized delta-8-THC and delta-9-THC effects in healthy adults; within-subject crossover trial. j.drugalcdep.2025.112684
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Psychotropic side effects were described as negligible.supported
Side effects negligible. pmid:7776837
A subsequent systematic review confirmed CT-3 among cannabinoid-based analgesics with positive efficacy signals for neuropathic pain.supported
22 RCTs including CT-3 (1',1'-dimethylheptyl-delta-8-THC-11-oic acid). 15 studies showed significant pain reduction. biom15060816
Δ8-THC reduces intraocular pressure in rabbit models, alongside Δ9-THC, cannabinol, and nabilonesupported
Δ8-THC and derivatives active in lowering IOP. pmid:6329602
receptor-pharmacology5 · 1 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Structure-activity relationship studies of Δ8-THC side-chain analogs demonstrate that affinity and efficacy at CB1 can be separated — modifications to the C-3 alkyl chain alter intrinsic efficacy independently of binding affinity.supported
Flexibility of side-chain affects efficacy differentially from affinity. pmid:11159703
Claim in receptor-pharmacology — not_supportednot supportedworking →
Claim in receptor-pharmacology — not_supportednot supportedworking →
chemistry4 · 1 ok
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
Stability is pH-dependent: significant degradation occurs at pH 1.2 (simulating gastric acid conditions), while the compound remains stable at physiological pH (7.4)supported
Significant degradation at pH 1.2 but stable at other pH values studied. s12249-011-9639-5
Claim in chemistry — inconclusiveinconclusiveworking →
pharmacokinetic-detail4 · 2 ok
The clearance value of 5.6 L/h/kg exceeds estimated rat hepatic blood flow, indicating the presence of extrahepatic clearance mechanisms — consistent with the lipophilic partitioning of cannabinoids into adipose and other peripheral tissues.supported
IV: clearance 5.6 L/h/kg, Vd 108.4 L/kg, t1/2 13.9h... Extrahepatic clearance indicated. bkaf105
Repeated oral dosing over 14 days produces plasma accumulation, suggesting that steady-state concentrations may be significantly higher than those predicted from single-dose pharmacokinetics.supported
Accumulation of D8-THC in plasma after 14 days observed. can.2023.0066
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
comparative-pharmacology3 · 0 ok
history3 · 3 ok
Treasury Department Narcotics Laboratorysupported
Roger Adams at University of Illinois initiated Cannabis chemistry exploration 1939-1942 with Treasury Dept Narcotics Lab. s42238-020-00031-3
Δ8-THC was first isolated from naturally grown cannabis in 1966, described as occurring "in very low yield" in marijuana cultivated in Marylandsupported
Notes 1966 isolation from Maryland marijuana at low yield. molecules29061249
Psychotropic side effects were described as negligible compared to Δ9-THCsupported
Side effects negligible. pmid:7776837
botanical-overview2 · 2 ok
Natural abundance is very low — typically less than 1% of the total phytocannabinoid fractionsupported
Notes 1966 isolation from Maryland marijuana at low yield. molecules29061249
Whether this trace presence represents genuine biosynthesis or is an artifact of oxidative conversion from Δ9-THC during drying, curing, or analytical processing remains actively debated.supported
Discusses whether natural compound vs. artifact. molecules29061249